Therapy of Acute Promyelocytic Leukemia

Advances in Pharmacology

Volumn 51, Issue , 2004, Pages 35-58

  Soignet, Steven ^a   Maslak, Peter ^b  

^a New York Gyn Oncology PC   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RETINOIC ACID;

GENETICS; HUMAN; METABOLISM; PATHOLOGY; PROMYELOCYTIC LEUKEMIA; RECURRENT DISEASE; REVIEW;

HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; RECURRENCE; TRETINOIN;

EID: 16544375942     PISSN: 10543589     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1054-3589(04)51002-5     Document Type: Article

References (94)

1. P.C. Adamson J. Bailey J. Pluda D.G. Poplack S. Bauza R.F. Murphy R. Yarchoan F.M. Balis Pharmacokinetics of all- trans retinoic acid administered on an intermittent schedule J. Clin. Oncol 13 1995 1238 1241
2. C. Arnould C. Phillippe V. Bourdon M.J. Grgoire R. Berger P. Jonveaux The signal transducer and activator of transcription STAT5b gene is a new partner of retinoic acid receptor alpha in acute promyelocytic-like leukaemia Hum. Mol. Genet 8 1999 1741 1749
3. G. Avvisati AIDA protocol: The Italian way of treating APL [abstract] Br. J. Hematol 102 1998 593a
4. G. Avvisati F. Mandelli M.C. Petti M.L. Vegna A. Spadea V. Liso G. Specchia C. Bernasconi E.P. Alessandrino C. Piatti Idarubicin (4-demethoxydaunorubicin) as single agent for remission induction of previously untreated acute promyelocytic leukemia: A pilot study of the Italian cooperative group GIMEMA Eur. J. Haematol 44 1990 257 260
5. J.T. Barbey J.C. Pezzullo S.L. Soignet Effects of arsenic trioxide on QT interval in patients with advanced malignancies J. Clin. Oncol 21 2003 19
6. C.D. Bloomfield Post-remission therapy in acute myeloid leukemia J. Clin. Oncol 3 1985 1570 1572
7. A.K. Burnett D. Grimwade E. Solomon K. Wheatley A.H. Goldstone Presenting white blood cell count and kinetics of molecular remission predicts prognosis in acute promyelocytic leukemia treated with all- trans retinoic acid: Results of the randomized MRC trial Blood 93 1999 4131 4143
8. I.H. Camacho S.L. Soignet S. Chanel R. Ho R.P. Warrell Jr. Leukocytosis and the retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide J. Clin. Oncol 18 2000 2620 2625
9. S. Castaigne C. Chomienne M.T. Daniel P. Ballerini R. Berger P. Fenaux L. Degos All- trans retinoic acid as a differentiating therapy for acute promyelocytic leukemias. I. Clinical results Blood 76 1990 1704 1713
10. 4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR α ⧸PML proteins Blood 88 1996 1052 1061
11. F.A. Crecelius Changes in the chemical speciation of arsenic following ingestion by man Environ. Health Perspect 19 1977 147 150
12. S. De Botton H. Dombret M. Sanz J.S. Miguel D. Caillot R. Zittoun M. Gardembas A. Stamatoulas E. Conde A. Guerci C. Gardin K. Geiser D.C. Makhoul O. Reman J. de la Serna F. Lefrere C. Chomienne C. Chastang L. Degos P. Fenaux Incidence, clinical features, and outcome of all- trans -retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia Blood 92 1998 2712 2718
13. β integrin heterodimers during retinoic acid-induced neuronal differentiation of murine embryonal carcinoma cells J. Biol. Chem 266 1991 21846 21852
14. L. Delva M. Cornic N. Balitrand F. Guidez J.M. Miclea A. Delmer F. Teillet P. Fenaux S. Caistaigne L. Degos Resistance to all- trans retinoic acid (ATRA) therapy in relapsing acute promyelocytic leukemia: Study of in vitro ATRA sensitivity and cellular retinoic acid binding protein levels in leukemic cells Blood 82 1993 2175 2181
15. H. de Thé C. Chomienne M. Lanotte L. Degos A. Dejean The t(15;17) translocation of acute promyelocytic leukemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus Nature 347 1990 558 561
16. E. Di Bona G. Avvisati G. Castaman V. Luce M. Vegna V. De Sanctis F. Rodeghiero F. Mandelli Early haemorrhagic morbidity and mortality during remission induction with or without all- trans retinoic acid in acute promyelocytic leukemia Br. J. Haematol 108 2000 689 695
17. R. Di Noto C. Lo Pardo F.M. Schiavone F. Ferrara C. Manzo C. Vacca L. Del Vecchio All- trans retinoic acid (ATRA) and the regulation of adhesion molecules in acute myeloid leukemia Leuk. Lymphoma 2 1996 201 209
18. D. Diverio V. Rossi G. Avvisati S. DeSantis A. Pistilli F. Pane G. Saglio G. Martinelli M.C. Petti A. Santoro P.G. Pelicei F. Mandelli A. Biondi F. Lo Coco Early detection of relapse by prospective reverse transcriptase-polymerase chain reaction analysis of the PML⧸RARα fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter “AIDA” trial Blood 92 1998 784 789
19. D. Douer E. Estey S. Santillana J.M. Bennett G. Lopez-Bernstein K.N. Boehm T. Williams Treatment of newly diagnosed and relapsed acute promyelocytic leukemia with intravenous liposomal all- trans retinoic acid Blood 97 1 2001 73 80
20. R.I. Drapkin T.S. Gee M.D. Dowling Z. Arlin S. McKenzie S. Kempin B. Clarkson Prophylactic heparin therapy in acute promyelocytic leukemia Cancer 41 1978 2484 2490
21. E.H. Estey F.J. Giles M. Beran S. O'Brien S.A. Pierce S.H. Faderl J.E. Cortes H.M. Kantarjian Experience with gemtuzumab ozogamycin (“myelotarg”) and all- trans retinoic acid in untreated acute promyelocytic leukemia Blood 99 11 2002 4222 4224
22. G.D. Evans D.J. Grimwade Extramedullary disease in acute promyelocytic leukemia Leuk. Lymphoma 33 3⧸4 1999 219 229
23. P. Fenaux C. Chastang S. Chevret M. Sanz H. Dombert E. Archimbaud M. Fey C. Rayon F. Huguet J.J. Sotto C. Gardin P.C. Makhoul P. Travade E. Solary N. Fegueux D. Bordessoule J.S. Miguel H. Link B. Desablens A. Stamatoullas E. Deconinck F. Maloisel S. Castaigne C. Preudhomme L. Degos A randomized comparison of all trans -retinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group Blood 94 4 1999 1192 1200
24. P. Fenaux C. Chastang C. Chomienne L. Degos Tretinoin with chemotherapy in newly diagnosed acute promyelocytic leukemia: Results Lancet 343 1994 1033
25. P. Fenaux C. Chomienne L. Degos All- trans retinoic acid and chemotherapy in the treatment of acute promyelocytic leukemia Semin. Hematol 38 1 2001 13 25
26. P. Fenaux M.C. Le Dely S. Castaigne E. Archimbaud C. Chomienne H. Link A. Guerci M. Duarte M.T. Daniel D. Bowe Effect of all- trans retinoic acid in newly diagnosed acute promyelocytic leukemia: Results of a multicenter randomized trial Blood 82 1993 3241 3249
27. F. Ferrara F. Morabito B. Martino G. Specchia V. Liso F. Nobile P. Boccuni R. DiNoto F. Pane M. Annunziata E.M. Schiavone M. De Simone C. Guglielmi L. Del Vecchio F. Lo Coco CD56 expression is an indicator of poor clinical outcome in patients with acute promyelocytic leukaemia treated with simultaneous ATRA and chemotherapy J. Clin. Oncol 18 2000 1295 1300
28. S.R. Frankel A. Eardley G. Heller E. Berman W.H. Miller Jr. E. Dmitrovsky R.P. Warrell Jr. All- trans retinoic acid for acute promyelocytic leukemia: Results of the New York study Ann. Intern. Med 120 1994 278 286
29. S.R. Frankel A. Eardley G. Lauwers M. Weiss R.P. Warrell Jr. The “retinoic acid syndrome” in acute promyelocytic leukemia Ann. Intern. Med 117 1992 292 296
30. H.M. Golomb J.D. Rowley J.W. Vardiman J.R. Testa A. Butler Microgranular acute promyelocytic leukaemia: A distinct clinical, ultrastructural, and cytogenetic entity Blood 55 1980 253 259
31. H.R. Gralnick J. Bagley E. Abrell Heparin treatment for the hemorrhagic diathesis of acute promyelocytic leukemia Am. J. Med 52 1972 167 174
32. D. Grimwade K. Howe S. Langabeer L. Davies F. Oliver H. Walker D. Swirsky K. Wheatley A. Goldstone A. Burnett E. Solomon Minimal residual disease detection in acute promyelocytic leukemia by reverse-transcriptase PCR: Evaluation of PML-RARα and RARα-PML assessment in patients who ultimately relapse Leukemia 10 1996 61 66
33. F. Guidez S. Ivins J. Zhu M. Soderstrom S. Waxman A. Zelent Reduced retinoic acid-sensitivities of nuclear receptor corepressor binding to PML- and PLZF-RARalpha underlie molecular pathogenesis and treatment of acute promyelocytic leukemia Blood 91 1998 2634 2642
34. I.Z. He F. Guidez C. Tribioli D. Peruzzi M. Ruthardt A. Zelent P.P. Pandolfi Distinct interactions of PML-RARalpha and PLZF-RARalpha with co-repressors determine differential responses to RA in APL Nat. Genet 18 1998 126 135
35. D. Head K.J. Kopecky J. Weick J.C. Files D. Ryan K. Foucar M. Montiel J. Bickers A. Fishleder M. Miller Effect of aggressive daunorubicin therapy on survival in acute promyelocytic leukemia Blood 86 1995 1717 1728
36. M.E. Huang Y.C. Ye S.R. Chen J.R. Chai J.X. Lu L. Zhoa L.J. Gu Z.Y. Wang Use of all- trans retinoic acid in treatment of acute promyelocytic leukemia Blood 72 1988 567 572
37. M.E. Huang Y.C. Ye S.R. Chen J.C. Zhoa L.J. Gu J.R. Cai L. Zhao J.X. Xie Z.X. Shen Z.Y. Wang All- trans retinoic acid with or without low dose cytosine arabinoside in acute promyelocytic leukemia—report of 6 cases Chin. Med. J 100 1987 949 953
38. J.G. Jurcic S.D. Nimer D. Scheinberg T. DeBlasio R.P. Warrell Jr. W.H. Miller Jr. Prognostic significance of minimal residual disease detection and PML⧸RAR-isoform type: Long-term follow-up in acute promyelocytic leukemia Blood 98 2001 2651 2656
39. A. Kakizuka W.H. Miller K. Umesono R.P. Warrell Jr. S.R. Frankel V.V. Murty E. Dmitrovsky R.M. Evans Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RARα with a novel putative transcription factor, PLL Cell 66 1991 663 674
40. H. Kantarjian M.J. Keating R.S. Walters E. Estey K.B. McCredie T.L. Smith W.T. Dalton Jr. A. Cork J.M. Trujillo E.J. Freireich Acute promyelocytic leukemia: MD Anderson Hospital experience Am. J. Med 80 1986 789 797
41. H.M. Kantarjian M.J. Keating R.S. Walters T.L. Smith K.B. McCredie E.J. Freireich Role of maintenance chemotherapy in acute promyelocytic leukemia Cancer 59 7 1987 1258 1263
42. B.-S. Ko G.-L. Tang Y.-C. Chen M. Yao G.H. Wang M.C. Shen H.F. Tien Extramedullary relapse after all- trans retinoic treatment in acute promyelocytic leukemia: The occurrence of retinoic acid syndrome is a risk factor Leukemia 13 1999 1406 1408
43. S.C. Kogan Acute promyelocytic leukemia: A view from a mouse Blood Cells Mol. Dis 26 2000 620 625
44. R.A. Larson K. Kondo J.W. Vardiman A.E. Butler H.M. Golomb J.D. Rowley Evidence for a 15;17 translocation in every patient with acute promyelocytic leukemia Am. J. Med 76 1984 827 841
45. E. Lengfelder A. Reichert C. Schoch D. Haase T. Haferlach H. Loffler P. Staib A. Heyll W. Seifarth S. Saussele C. Fonatsch W. Gassmann W.D. Ludwig A. Hochhaus D. Beelen C. Aul M.C. Sauerland A. Heinecke R. Hehlmann B. Wormann W. Hiddemann T. Buchner Double induction strategy including high-dose cytarabine in combination with all- trans retinoic acid: Effects in patients with newly diagnosed acute promyelocytic leukemia Leukemia 14 2000 1362 1370
46. Y.-P. Li F. Said R.E. Gallagher Retinoic acid-resistant HL-60 cells exclusively contain mutant retinoic acid receptor Blood 11 1994 3298 3302
47. J.D. Licht C. Chomienne A. Goy A. Chen A.A. Scott D.R. Head J.L. Michaux Y. Wu A. DeBlasio W.H. Miller Jr. Clinical and molecular characterization of a rare syndrome of acute promyelocytic leukemia associated with trans -location (11;17) Blood 85 1995 1083 1094
48. V. Liso G. Specchia E.M. Pogliani G. Palumbo D. Mininni V. Rossi E. Teruzzi A. Mestice M.R. Coppi A. Biondi Extramedullary involvement in patients with acute promyelocytic leukemia: A report of seven cases Cancer 83 1998 1522 1528
49. F. Lo Coco G. Avvisati D. Diverio M.C. Petti M. Alcalay P.P. Pandolfi D. Zangrilli A. Biondi A. Rambaldi M. Moleti Molecular evaluation of response to all- trans retinoic acid therapy in patients with acute promyelocytic leukemia Blood 77 1991 1657 1661
50. F. Lo Coco D. Diverio P.P. Pandolfi A. Biondi V. Rossi G. Avvisati A. Rambaldi W. Arcese M.C. Petti G. Melani Molecular evaluation of residual disease as a predictor of relapse in acute promyelocytic leukemia Lancet 340 1992 1437 1438
51. F. Mandelli D. Diverio G. Avvisati A. Luciano T. Barbui C. Bernasconi G. Broccia M. Falda G. Fioritoni F. Leoni V. Liso M.C. Petti F. Rodeghiero G. Saglio M.L. Vegna G. Visani U. Jehn R. Willemze P. Muus P.G. Pelicci A. Biondi F. Lo Coco Molecular remission in PML⧸RAR alpha-positive acute promyelocytic leukemia by combined all- trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups Blood 90 3 1997 1014 1021
52. S. Mann P.O. Droz M. Vahter A physiologically based pharmacokinetic model for arsenic exposure. II. Validation and application in humans Toxicol. Appl. Pharmacol 140 1996 471 486
53. R. Marra S. Storti L. Pagano G. Fioritoni C. Rabitti S. Sica G. Leone G. Torlontano B. Bizzi Central nervous system acute promyelocytic leukemia: A report of three cases Haematologica 22 1989 195 199
54. M. Marty G. Ganem J. Fischer G. Flandrin R. Berger G. Schaison L. Degos M. Boiron Acute promyelocytic leukemia: Retrospective study of 119 patients treated with daunorubicin Nouv. Rev. Fr. Hematol 26 1984 371 387
55. R.W. McKenna J. Parkin C.D. Bloomfield R.D. Sundberg R.D. Brunning Acute promyelocytic leukaemia: A study of 39 cases with identification of a hyperbasophilic microgranular variant Br. J. Haematol 50 1982 201 214
56. G. Meloni D. Diverio M. Vignetti G. Avvisati S. Capria M.C. Petti F. Mandelli F. Lo Coco Autologous bone marrow transplantation for acute promyelocytic leukemia in second remission: Prognostic relevance of pretransplant minimal residual disease assessment by reverse-transcription polymerase chain reaction of the PML⧸RAR alpha fusion gene Blood 90 1997 1321 1325
57. A. Menendez A. Gonzales H. Cabrera J. Mesa G. Martinez E. Espinoza P. Hernandez Clinical spectrum of extramedullary acute promyelocytic leukemia Eur. J. Haematol 64 2000 201 203
58. W.H. Miller Jr. A. Kakizuka S.R. Frankel R.P. Warrell Jr. A. DeBlasio K. Levine R.M. Evans E. Dmitrovsky Reverse transcription polymerase chain reaction for the re-arranged retinoic acid receptor clarifies diagnosis and detects minimal residual disease in acute promyelocytic leukemia Proc. Natl. Acad. Sci. USA 89 1992 2694 2698
59. W.H. Miller Jr. K. Levine A. De Blasio S.R. Frankel E. Dmitrovsky R.P. Warrell Jr. Detection of minimal residual disease in acute promyelocytic leukemia by a reverse transcription polymerase chain reaction Blood 82 1993 1689 1694
60. J. Muindi S.R. Frankel W.H. Miller Jr. A. Jakubowski D.A. Scheinberg C.W. Young E. Dmitrovsky R.P. Warrell Jr. Continuous treatment with all- trans retinoic acid results in a progressive decrease in plasma concentrations: Implications for relapse and “resistance” in acute promyelocytic leukemia Blood 79 1992 299 303
61. J.F. Muindi H.I. Scher J.R. Rigas R.P. Warrell Jr. C.W. Young Elevated plasma lipid peroxide content correlates with rapid plasma clearance of all- trans retinoic acid in patients with advanced cancer Cancer Res 54 1994 2125 2158
62. M.C. Petti G. Avvisati S. Amadori M. Baccarani A.R. Guarini G. Papa G.A. Rosti S. Tura F. Mandelli Acute promyelocytic leukemia: Clinical aspects and results of treatment in 62 patients Haematologica 72 1987 151 155
63. M.C. Petti M.B. Pinazzi D. Diverio A. Romano M.T. Petrucci S. De Santis G. Meloni A. Tafuri F. Mandelli F. Lo Coco Prolonged molecular remission in advanced acute promyelocytic leukaemia after treatment with gemtuzumab ozogamicin (Mylotarg CMA-676) Br. J. Haematol 115 1 2001 63 65
64. E. Raffoux P. Rousselot J. Poupon M.T. Daniel B. Cassinat R. Delarue A.L. Taksin D. Rea A. Buzyn A. Tibi G. Lebbe P. Cimerman C. Chomienne J.P. Fermand H. de The L. Degos O. Hermine H. Dombret Combined treatment with arsenic trioxide and all- trans -retinoic acid in patients with relapsed acute promyelocytic leukemia J. Clin. Oncol 21 12 2003 2326 2334
65. R.L. Redner J.D. Chen E.A. Rush H. Li S.L. Pollock The t(5;17) acute promyelocytic leukemia fusion protein NPM-RAR interacts with co-repressor and co-activator proteins and exhibits both positive and negative transcriptional properties Blood 95 2000 2683 2690
66. K.A. Robertson B. Emami S.J. Collins Retinoic acid-resistant HL-60R cells harbor a point mutation in the retinoic acid receptor ligand-binding domain that confers dominant negative activity Blood 80 1992 1885 1889
67. J. Rowley H.M. Golomb C. Dougherty 15⧸17 trans -location, a consistent chromosomal change in acute promyelocytic leukemia Lancet 1 1997 549 550
68. D.M. Rust S.L. Soignet Risk⧸benefit profile of arsenic trioxide The Oncologist 6 Suppl. 2 2001 29 32
69. D. Sainty V. Liso A. Cantu-Rajnoldi D. Head M.J. Mozziconacci C. Arnoulet L. Benattas S. Fenu M. Mancini E. Duchayne E.X. Mahon N. Gutierrez E. Birg A. Biondi D. Grimwade M. Lafage-Pochitaloff F.G. Hagemijer A new morphological classification system for acute promyelocytic distinguishes cases with underlying PLZF-RAR_rearrangements Blood 96 2000 1287 1296
70. M.A. Sanz G. Martin C. Rayon J. Esteve M. Gonzalez J. Diaz-Mediavilla P. Bolufer E. Barragan M.J. Terol J.D. Gonzalez D. Colomer C. Chillon C. Rivas T. Gomez J.M. Ribera R. Bornstein J. Roman M.J. Calasanz J. Arias Alvarez F. Ramos G. Deben A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML⧸RAR-alpha-positive acute promyelocytic leukemia Blood 94 1999 3015 3021
71. D.A.S. Scheinberg P. Maslak M.A. Weiss Acute leukemias V. De Vita S. Hellman S.A. Rosenberg “Cancer: Principles and Practice of Oncology” 6th ed. 2001 Lippincott Williams & Wilkins Philadelphia, PA
72. 3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients Blood 89 1997 3354 3360
73. S.L. Soignet Clinical experience of arsenic trioxide in relapsed acute promyelocytic leukemia The Oncologist 6 Suppl. 2 2001 11 16
74. S.L. Soignet S.R. Frankel D. Douer M.S. Tallman H. Kantarjian E. Calleja R.M. Stone M. Kalaycio D.A. Scheinberg P. Steinherz E.L. Sievers S. Coutre S. Dahlberg R. Ellison R.P. Warrell Jr. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia J. Clin. Oncol 19 2001 3852 3860
75. S.L. Soignet P. Maslak Z.-G. Wang S. Jhanwar E. Calleja L.J. Dandasht D. Corso A. De Blasio J. Gabrilove D.A. Scheinberg P.P. Pandolfi R.P. Warrell Jr. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide N. Engl. J. Med 339 1998 1341 1348
76. 3): A dose-ranging study and clinical pharmacologic study in patients with advanced hematologic cancers Proc. Am. Assoc. Cancer. Res 2000 3462 (abs).
77. S. Soignet Z.-G. Wang J. Nagy P. Maslak S. Chanel R. Ho D. Spriggs R. Ellison P.P. Pandolfi R.P. Warrell Jr. Dose-ranging study of arsenic trioxide in advanced hematologic cancers: Clinical pharmacokinetics and biological effects Blood 92 Suppl. 1 1998 2466 (abs).
78. G. Specchia E. Lo Coco M. Vignetti G. Avyisati P. Fazi F. Albano F. Di Raimondo B. Martino F. Ferrara C. Selleri V. Liso F. Mandelli Extramedullary involvement at relapse in acute promyelocytic leukemia patients treated or not treated with all- trans retinoic acid: A report by the Gruppo Italiano Malattie Ematologiche dell'Adulto J. Clin. Oncol 19 20 2001 4023 4028
79. H.D. Sun L. Ma X.C. Hu T.D. Zhang Ai-Lin 1 treated 32 cases of acute promyelocytic leukemia Chin. J. Integrat. Chin. West. Med 12 1992 170 171
80. M.S. Tallman J.W. Andersen C.A. Schiffer F.R. Appelbaum J.H. Feusner A. Ogden L. Shepard C. Willman C.D. Bloomfield J.M. Rowe P.H. Wiernik All- trans retinoic acid in acute promyelocytic leukemia N. Eng. J. Med 337 15 1997 1021 1028
81. M.S. Tallman C. Nabhan J.H. Feusner J. Rowe Acute promyelocytic leukemia: evolving therapeutic strategies Blood 99 3 2002 759 767
82. X. Thomas H. Dombret C. Cordonnier A. Pigneux C. Gardin A. Guerci A. Vekhoff A. Sadoun A. Stamatoullas N. Fegueux E. Maloisel J.T. Cahn O. Reman N. Gratecos C. Berthou F. Huguet P. Kotoucek P. Trauade A. Buzyn T. de Rowel J.P. Vilque P. Naccache C. Chomienne L. Degos P. Fenaux Treatment of relapsing acute promyelocytic leukemia by all- trans retinoic acid therapy followed by timed sequential chemotherapy and stem cell transplantation Leukemia 12 2000 1006 1013
83. D. Unnikrishnan J.P. Dutcher N. Varshneya R. Lucariello M. Api S. Garl P.H. Wiernik S. Chiaramida Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide Blood 97 2001 1514 1516
84. L. Vahdat P. Maslak W.H. Miller Jr. A. Eardley G. Heller D.A. Scheinberg R.P. Warrell Jr. Early mortality and the retinoic acid syndrome in acute promyelocytic leukemia: Impact of leukocytosis, low-dose chemotherapy, PMN⧸RAR-alpha isoform, and CD13 expression in patients treated with all- trans retinoic acid Blood 84 1994 3843 3849
85. R.P. Warrell Jr. Pathogenesis and management of acute promyelocytic leukemia Annu. Rev. Med 47 1996 555 565
86. R.P. Warrell Jr. Retinoid resistance in acute promyelocytic leukemia: New mechanisms, strategies, and implications [editorial] Blood 82 1993 1949 1953
87. R.P. Warrell Jr. S.R. Frankel W.H. Miller Jr. D.A. Scheinberg L. Itri W.N. Hittelman R. Vyas M. Andreeff A. Tafuri A. Jakubowski J. Gabrilove M. Gordon E. Dmitrovsky Differentiation therapy of acute promyelocytic leukemia with tretinoin (all- trans -retinoid acid) N. Eng. J. Med 324 1991 1385 1393
88. R.P. Warrell Jr. P. Maslak A. Eardley G. Heller W.H. Miller Jr. S.R. Frankel Treatment of acute promyelocytic leukemia with all- trans retinoic acid: An update of the New York experience Leukemia 8 1994 929 933
89. R.A. Wells C. Catzavelos S. Kamel-Reid Fusion of retinoic acid receptorα to NUMA, the nuclear mitotic apparatus protein, by a variant translocation in acute promyelocytic leukaemia Nat Genet 17 1997 109 113
90. M.A. Weiss R.P. Warrell Jr. Two cases of extramedullary acute promyelocytic leukemia Cancer 74 1994 1882 1886
91. P. Westervelt R.A. Brown D.R. Adkins H. Khury P. Curtin D. Hurd S.M. Luger M.K. Ma T.J. Ley J.F. DiPersio Sudden cardiac death among patients with acute promyelocytic leukemia treated with arsenic trioxide Blood 98 2001 266 271
92. J.S. Wiley F.C. Firkin Reduction of pulmonary toxicity by prednisone prophylaxis during all- trans retinoic acid treatment of acute promyelocytic leukemia Leukemia 9 1995 774 778
93. Z. Zhang G. Tarone D.C. Turner Expression of integrin α1β1 is regulated by nerve growth factor and dexamethasone in PC12 cells: Critical consequences for adhesion and neurite outgrowth J. Biol. Chem 268 1993 5557 5565
94. P. Zhang S.Y. Wang L.H. Hu Arsenic trioxide treated 72 cases of acute promyelocytic leukemia Chin. J. Hematol 2 1996 58 62